CytoDyn
Biotechnology ResearchWashington, United States11-50 Employees
CytoDyn, a small-to-mid-sized biotechnology firm based in Vancouver, Washington, is advancing leronlimab, a CCR5 receptor antagonist, through late-stage clinical development as a platform therapy for several indications, including HIV, nonalcoholic steatohepatitis (NASH), NASH/HIV, and oncology. Leronlimab is a humanized monoclonal antibody administered as a once-a-week subcutaneous injection and can also be given intravenously; it works by competitively inhibiting the CCR5 receptor, a distinct mechanism from other CCR5-targeting therapies. The CCR5 receptor is present on immune cells and other cell types involved in inflammation, fibrosis, and cancer, and it functions as a receptor for chemokines that guide leukocyte movement, as well as serving as a co-receptor for certain HIV strains. CytoDyn's programs span oncology and neurodegenerative indications as it seeks to apply leronlimab beyond HIV and liver-related disease. A recent development noted in 2026 is the initiation of a Phase 2a Alzheimer's disease study conducted in collaboration with Weill Cornell Medicine, with the first patient dosed.
1-888-653-2347 
support@leadiq.com 
